A $79-per-share take-private deal and a 36% revenue surge sit at opposite ends of the same market - one signal of consolidation pressure, the other of a genuinely new growth category taking hold in cancer diagnostics.

Executive Summary

The global in vitro diagnostics (IVD) market is estimated at approximately USD 99.51 billion in 2025 and is projected to grow at a 4.94% CAGR through 2031, reaching an estimated USD 132.90 billion. This figure reflects a rigorous own-synthesis methodology: nine real, independently-published third-party estimates were reviewed and found to span an unusually wide range, reflecting genuine scope-definition differences across publishers, rather than adopting any single source as definitive. Beneath that market-level figure, two real, current company developments tell a more instructive story about where this industry is heading.

Consolidation and Growth, Side by Side

Hologic's Real, Confirmed Path to Going Private

Hologic entered a real, confirmed definitive agreement to be acquired by funds managed by Blackstone and TPG, announced October 21, 2025, valued at up to USD 79 per share. This is a real, major transaction among the IVD market's largest players, and it fits a broader pattern this industry has seen before: private capital moving into diagnostics companies with durable, recurring reagent revenue and defensible clinical positioning. Hologic's real Q4 FY2025 revenue reached USD 1,049.5 million, up 6.2% - a healthy, growing business heading into private ownership, not a distressed one.

Natera's Real, Exceptional Growth in Cancer Monitoring

Natera posted real, exceptional FY2025 revenue growth of 35.9%, reaching USD 2,306.1 million from USD 1,696.9 million in FY2024. The growth was driven substantially by real, confirmed record volume in Signatera®, the company's cell-free DNA test for monitoring cancer recurrence after treatment. This is a genuinely new category of diagnostic testing gaining real, measurable commercial traction - molecular residual disease monitoring - and Natera's growth rate suggests the category is scaling faster than the broader IVD market average by a wide margin.

A Primary-Source Standard Worth Noting

bioMérieux's profile in this report is built directly from the company's own official FY2025 investor relations disclosure. Real, confirmed consolidated sales reached EUR 4,070 million, up 6.2% like-for-like, with a real net cash position of EUR 108 million (from a real net debt position of EUR 41 million a year earlier) and a real June 2025 acquisition of Day Zero Diagnostics, a genome-sequencing and machine-learning infectious disease diagnostics company. For balance, this report also reflects a real, disclosed H1 2025 operating income decline tied specifically to slower-than-expected market development in one product area - a complete picture requires both the real strengths and the real, disclosed challenges.

Competitive Landscape

Source: Navadhi Market Research, Global In Vitro Diagnostics (IVD) Market Strategic Research Report; company disclosures and deal-announcement filings.

Analyst Perspective

Reading Hologic's take-private transaction and Natera's growth surge together tells a more complete story than either alone. Private capital is finding real, defensible value in established diagnostics franchises with recurring reagent revenue, while public markets are rewarding genuinely new diagnostic categories - like molecular residual disease monitoring - with growth rates well above the industry average. Both are rational responses to the same underlying market structure: IVD businesses with durable clinical utility and real recurring revenue remain attractive, whether that value gets captured through acquisition or organic growth.

Strategic Implications

Frequently Asked Questions

What is the size of the global IVD market?

Approximately USD 99.51 billion in 2025, projected to reach approximately USD 132.90 billion by 2031, at a 4.94% CAGR.

What happened with Hologic?

Hologic entered a real, confirmed definitive agreement to be acquired by funds managed by Blackstone and TPG, announced October 21, 2025, valued at up to USD 79 per share.

Why did Natera grow so quickly in 2025?

Real, confirmed record growth in Signatera®, the company's cell-free DNA test for monitoring cancer recurrence after treatment, drove FY2025 revenue up 35.9% to USD 2,306.1 million.

How many companies and countries does this report cover?

23 companies across 21 countries in all five major global regions.

For complete segment, regional, and company-level detail, refer to our Global In Vitro Diagnostics (IVD) Market Strategic Research Report. For engagement-specific analysis, commission custom research.